



**SZABO  
SCANDIC**

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](http://linkedin.com/company/szaboscandic)



# CYP2S1 (h3): 293T Lysate: sc-174576

## BACKGROUND

The cytochrome P450 proteins are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. P450 enzymes are classified into subfamilies based on their sequence similarities. CYP2S1, a member of the CYP2 subfamily, is expressed in a wide variety of epithelial cells in extrahepatic tissues; specifically the respiratory tract, gastrointestinal tract, skin and other tissues frequently exposed to xenobiotics. CYP2S1 localizes to the endoplasmic reticulum where it metabolizes both endogenous and exogenous substrates, such as retinoic acid, aromatic hydrocarbons and some cellular substances. CYP2S1 is also involved in the metabolism of topical drugs and mediates the response to photochemotherapy in psoriasis. Dioxin induces CYP2S1, while aryl hydrocarbon receptor (AHR) and aryl hydrocarbon nuclear translocator (ARNT) regulate this induction.

## REFERENCES

1. Rylander, T., Neve, E.P., Ingelman-Sundberg, M. and Oscarson, M. 2001. Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1). *Biochem. Biophys. Res. Commun.* 281: 529-535.
2. Smith, G., Wolf, C.R., Deeni, Y.Y., Dawe, R.S., Evans, A.T., Comrie, M.M., Ferguson, J. and Ibbotson, S.H. 2003. Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. *Lancet* 361: 1336-1343.
3. Saarikoski, S.T., Suttila, T., Holmila, R., Impivaara, O., Järvisalo, J., Hirvonen, A. and Husgafvel-Pursiainen, K. 2004. Identification of genetic polymorphisms of CYP2S1 in a Finnish Caucasian population. *Mutat. Res.* 554: 267-277.
4. Choudhary, D., Jansson, I., Stoilov, I., Sarfarazi, M. and Schenkman, J.B. 2005. Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. *Arch. Biochem. Biophys.* 436: 50-61.
5. Ingelman-Sundberg, M. 2005. The human genome project and novel aspects of cytochrome P450 research. *Toxicol. Appl. Pharmacol.* 207: 52-56.
6. Karlgren, M., Miura, S. and Ingelman-Sundberg, M. 2005. Novel extrahepatic cytochrome P450s. *Toxicol. Appl. Pharmacol.* 207: 57-61.
7. Kumarakulasingham, M., Rooney, P.H., Dundas, S.R., Telfer, C., Melvin, W.T., Curran, S. and Murray, G.I. 2005. Cytochrome P450 profile of colorectal cancer: identification of markers of prognosis. *Clin. Cancer Res.* 11: 3758-3765.
8. Saarikoski, S.T., Rivera, S.P., Hankinson, O. and Husgafvel-Pursiainen, K. 2005. CYP2S1: A short review. *Toxicol. Appl. Pharmacol.* 207: 62-69.
9. Saarikoski, S.T., Wikman, H.A., Smith, G., Wolff, C.H. and Husgafvel-Pursiainen, K. 2005. Localization of cytochrome P450 CYP2S1 expression in human tissues by *in situ* hybridization and immunohistochemistry. *J. Histochem. Cytochem.* 53: 549-556.

## STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

## CHROMOSOMAL LOCATION

Genetic locus: CYP2S1 (human) mapping to 19q13.2.

## PRODUCT

CYP2S1 (h3): 293T Lysate represents a lysate of human CYP2S1 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

## APPLICATIONS

CYP2S1 (h3): 293T Lysate is suitable as a Western Blotting positive control for human reactive CYP2S1 antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.